Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

First Albany Stays 'Neutral' on Neopharma

First Albany keeps its neutral rating on Neopharma (NEOL)

Analyst David Webber says the news is an indication of the promise and potential of its maliglant tumore treatment, agent IL13-PE38. He says clinicians he spoke with are optimistic, given the current results. He notes the company often said it hopes to advance to pivotal clinical trials later this year or early next year. Webber thinks Neopharma has a diversified technolgy base, and a good chance of getting a product to market.

He sees a $1.92 2002 loss, and a $2.75 2003 loss. He says he is long term positive on Neopharma, however, he rates neutral because the company's problems with development partner Pharmacia is leading to binding arbitration.

blog comments powered by Disqus